Profusa Received ISO Certification for Quality System
Diagnostics companies targeting the European market must navigate new quality management standards to secure CE marking.
Updated on Sept. 24, 2026 in Healthcare
Live Poll
Do you trust the long-term potential of micro-cap stocks following positive regulatory news?
Profusa secured ISO 13485 quality management certification from GMED, a key milestone for the company's European Union Medical Device Regulation compliance efforts. Following the announcement, the company's stock price rose 50.70% to $3.08 on September 24, 2026.
Why it matters
ISO 13485 certification acts as a critical regulatory prerequisite for diagnostics manufacturers seeking CE marking within the European Union. Securing this status allows firms to move toward formal conformity assessments under updated EU medical device rules.
Profusa shares surged 50.70% to $3.08, significantly above the company's 52-week low of $1.58. The certification process supports a growth strategy that includes a July 2026 option to acquire G3 Vision Labs, which recorded $111 million in 2025 sales.
The players
Profusa
A medical technology company developing biosensor-based tissue diagnostics platforms.
GMED
A notified body providing regulatory assessments and quality management certification for medical devices in the European Union.
G3 Vision Labs
A diagnostics business with $111 million in annual sales currently targeted for potential acquisition.
The details
Profusa earned the ISO 13485 designation from GMED, an authorized notified body responsible for evaluating medical device compliance in the European Union. This certification validates the operational quality systems governing the Lumee Oxygen Platform, which utilizes biosensors to track tissue oxygen levels. The company is now working through further MDR assessment stages to obtain formal CE marking for its hardware.
Timeline
2025: G3 Vision Labs reported approximately $111 million in sales.
July 2026: Profusa signed an option agreement to acquire G3 Vision Labs.
September 24, 2026: Profusa received GMED certification and shares rose 50.70%.
Market Landscape
This development follows the implementation of the European Union Medical Device Regulation, which has heightened quality requirements for all manufacturers. The certification aligns Profusa with the stringent documentation standards now necessary to maintain market access.
Manufacturers of diagnostic hardware should monitor the progress of notified bodies like GMED as they process backlogs for MDR conformity. Ensure that internal quality management systems are regularly audited against ISO 13485 standards to avoid delays in CE marking approvals.
The takeaway
ISO 13485 compliance is a foundational step in navigating the current European medical device regulatory framework. Operators should prioritize audit-ready documentation to ensure they meet the rigorous assessment standards required by EU notified bodies.
Further reading
For additional context on sector-wide regulatory shifts, visit the Healthcare section.
Source note: This article includes information reported by Benzinga.
Live Poll
Do you trust the long-term potential of micro-cap stocks following positive regulatory news?
